Pacific Biosciences Of California (PACB) Inventory Average (2011 - 2026)

Pacific Biosciences Of California's Inventory Average history runs 16 years deep, the most recent figure standing at $50.2 million for Q1 2026.

• On a quarterly basis, Inventory Average fell 11.05% year-over-year to $50.2 million in Q1 2026; TTM through Mar 2026 was $50.2 million, a 11.05% decrease from a year earlier, with the FY2025 full-year figure at $54.0 million, down 6.4% from the prior year.
• Inventory Average fell to $50.2 million in Q1 2026 per PACB's latest filing, from $51.2 million in the prior quarter.
• Across five years, Inventory Average topped out at $68.0 million in Q2 2024 and bottomed at $27.1 million in Q1 2022.
• The 5-year median for Inventory Average is $56.2 million (2023), against an average of $54.3 million.
• Across the five-year window, Inventory Average jumped 107.17% in 2023 and dropped 20.66% in 2025, its largest moves.
• Year by year, Inventory Average stood at $46.9 million in 2022, then soared by 33.08% to $62.5 million in 2023, then slipped by 0.35% to $62.2 million in 2024, then declined by 17.72% to $51.2 million in 2025, then decreased by 2.08% to $50.2 million in 2026.
• Per Business Quant, the three latest PACB Inventory Average figures stand at $50.2 million (Q1 2026), $51.2 million (Q4 2025), and $53.5 million (Q3 2025).